492 related articles for article (PubMed ID: 9918216)
21. Carcinoembryonic antigen (CEA)-specific T-cell activation in colon carcinoma induced by anti-CD3 x anti-CEA bispecific diabodies and B7 x anti-CEA bispecific fusion proteins.
Holliger P; Manzke O; Span M; Hawkins R; Fleischmann B; Qinghua L; Wolf J; Diehl V; Cochet O; Winter G; Bohlen H
Cancer Res; 1999 Jun; 59(12):2909-16. PubMed ID: 10383154
[TBL] [Abstract][Full Text] [Related]
22. Tumor lymphocytes in patients with advanced ovarian cancer: changes during in vitro culture and implications for immunotherapy.
Han X; Papadopoulos AJ; Ruparelia V; Devaja O; Raju KS
Gynecol Oncol; 1997 Jun; 65(3):391-8. PubMed ID: 9190963
[TBL] [Abstract][Full Text] [Related]
23. Induction of immunocellular resistance to IL-2-activated lymphocytes within ovarian carcinoma cells.
Papadopoulos AJ; Han X; Matossian-Rogers A; Raju KS
Gynecol Oncol; 1995 Jun; 57(3):388-94. PubMed ID: 7774843
[TBL] [Abstract][Full Text] [Related]
24. Tumor specific cytolysis by tumor infiltrating lymphocytes in breast cancer.
Baxevanis CN; Dedoussis GV; Papadopoulos NG; Missitzis I; Stathopoulos GP; Papamichail M
Cancer; 1994 Aug; 74(4):1275-82. PubMed ID: 7914469
[TBL] [Abstract][Full Text] [Related]
25. Phenotyping of lymphocytes expressing regulatory and effector markers in infiltrating ductal carcinoma of the breast.
Leong PP; Mohammad R; Ibrahim N; Ithnin H; Abdullah M; Davis WC; Seow HF
Immunol Lett; 2006 Feb; 102(2):229-36. PubMed ID: 16246429
[TBL] [Abstract][Full Text] [Related]
26. Tumor antigen-specific T-cell expansion is greatly facilitated by in vivo priming.
Dang Y; Knutson KL; Goodell V; dela Rosa C; Salazar LG; Higgins D; Childs J; Disis ML
Clin Cancer Res; 2007 Mar; 13(6):1883-91. PubMed ID: 17363545
[TBL] [Abstract][Full Text] [Related]
27. Proportion of CD4+CD25+ regulatory T cell is increased in the patients with ovarian carcinoma.
Li X; Ye DF; Xie X; Chen HZ; Lu WG
Cancer Invest; 2005; 23(5):399-403. PubMed ID: 16193639
[TBL] [Abstract][Full Text] [Related]
28. Anti-CD3 x anti-tumor F(ab')2 bifunctional antibody activates and retargets tumor-infiltrating lymphocytes.
Chapoval AI; Nelson H; Thibault C
J Immunol; 1995 Aug; 155(3):1296-303. PubMed ID: 7636196
[TBL] [Abstract][Full Text] [Related]
29. Activation of T cell cytotoxicity against autologous common acute lymphoblastic leukemia (cALL) blasts by CD3xCD19 bispecific antibody.
Csóka M; Strauss G; Debatin KM; Moldenhauer G
Leukemia; 1996 Nov; 10(11):1765-72. PubMed ID: 8892680
[TBL] [Abstract][Full Text] [Related]
30. An effective strategy of human tumor vaccine modification by coupling bispecific costimulatory molecules.
Haas C; Herold-Mende C; Gerhards R; Schirrmacher V
Cancer Gene Ther; 1999; 6(3):254-62. PubMed ID: 10359211
[TBL] [Abstract][Full Text] [Related]
31. [Functional and phenotypic analysis of tumor infiltrating lymphocytes derived from solid tumors and effusion associated lymphocytes in malignant ascites cultured in recombinant interleukin 2].
Itoh K; Shiiba K; Ebina N; Anzai R; Ouchi A; Matsuno S
Nihon Geka Gakkai Zasshi; 1993 Aug; 94(8):781-90. PubMed ID: 8377752
[TBL] [Abstract][Full Text] [Related]
32. Tumor-infiltrating lymphocytes contain higher numbers of type 1 cytokine expressors and DR+ T cells compared with lymphocytes from tumor draining lymph nodes and peripheral blood in patients with cancer of the uterine cervix.
Santin AD; Ravaggi A; Bellone S; Pecorelli S; Cannon M; Parham GP; Hermonat PL
Gynecol Oncol; 2001 Jun; 81(3):424-32. PubMed ID: 11371133
[TBL] [Abstract][Full Text] [Related]
33. [Isolation and expansion of glioma-infiltrating lymphocytes in vitro: an analysis of their surface phenotypes and antitumor activities].
Sawamura Y
Hokkaido Igaku Zasshi; 1991 Nov; 66(6):868-78. PubMed ID: 1783372
[TBL] [Abstract][Full Text] [Related]
34. Activation and preferential expansion of rat cytotoxic (CD8) T cells in vitro and in vivo with a bispecific (anti-TCR alpha/beta x anti-CD2) F(ab')2 antibody.
Tutt AL; Reid R; Wilkins BS; Glennie MJ
J Immunol; 1995 Sep; 155(6):2960-71. PubMed ID: 7673714
[TBL] [Abstract][Full Text] [Related]
35. Purging of epithelial tumor cells from peripheral blood stem cells by means of the bispecific antibody BIS-1.
Schröder CP; Kroesen BJ; de Leij LF; de Vries EG
Clin Cancer Res; 2000 Jun; 6(6):2521-7. PubMed ID: 10873108
[TBL] [Abstract][Full Text] [Related]
36. Human T cells armed with Her2/neu bispecific antibodies divide, are cytotoxic, and secrete cytokines with repeated stimulation.
Grabert RC; Cousens LP; Smith JA; Olson S; Gall J; Young WB; Davol PA; Lum LG
Clin Cancer Res; 2006 Jan; 12(2):569-76. PubMed ID: 16428502
[TBL] [Abstract][Full Text] [Related]
37. GMP production of anti-tumor cytotoxic T-cell lines for adoptive T-cell therapy in patients with solid neoplasia.
Turin I; Pedrazzoli P; Tullio C; Montini E; La Grotteria MC; Schiavo R; Perotti C; Locatelli F; Carretto E; Maccario R; Siena S; Montagna D
Cytotherapy; 2007; 9(5):499-507. PubMed ID: 17786611
[TBL] [Abstract][Full Text] [Related]
38. T cell retargeting using bispecific monoclonal antibodies in a rat colon carcinoma model. II. Syngeneic colon carcinoma CC531 is efficiently killed by retargeted cytotoxic T lymphocytes in vitro despite limited lysis in 51Cr release assays.
Beun GD; Gorter A; Nooyen Y; van de Velde CJ; Fleuren GJ
J Immunol; 1993 Mar; 150(6):2305-15. PubMed ID: 8450213
[TBL] [Abstract][Full Text] [Related]
39. A parathyroid-hormone-related-protein (PTH-rP)-specific cytotoxic T cell response induced by in vitro stimulation of tumour-infiltrating lymphocytes derived from prostate cancer metastases, with epitope peptide-loaded autologous dendritic cells and low-dose IL-2.
Correale P; Micheli L; Vecchio MT; Sabatino M; Petrioli R; Pozzessere D; Marsili S; Giorgi G; Lozzi L; Neri P; Francini G
Br J Cancer; 2001 Nov; 85(11):1722-30. PubMed ID: 11742494
[TBL] [Abstract][Full Text] [Related]
40. Tumor-infiltrating lymphocytes from human ovarian cancer patients recognize autologous tumor in an MHC class II-restricted fashion.
Dadmarz RD; Ordoubadi A; Mixon A; Thompson CO; Barracchini KC; Hijazi YM; Steller MA; Rosenberg SA; Schwartzentruber DJ
Cancer J Sci Am; 1996; 2(5):263-72. PubMed ID: 9166543
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
